Search hospitals > California > Marysville
Fremont - Rideout Cancer Center
Claim this profileMarysville, California 95901
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
118 reported clinical trials
16 medical researchers
Summary
Fremont - Rideout Cancer Center is a medical facility located in Marysville, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Fremont - Rideout Cancer Center is involved with conducting 118 clinical trials across 260 conditions. There are 16 research doctors associated with this hospital, such as Edward J. Kim, Joseph M. Tuscano, Mamta Parikh, and Jonathan W. Riess.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Edward J. KimUniversity of California Davis Comprehensive Cancer Center1 year of reported clinical research
Studies Adenocarcinoma
Studies Cancer
30 reported clinical trials
68 drugs studied
Joseph M. TuscanoUniversity of California Davis Comprehensive Cancer Center4 years of reported clinical research
Expert in Lymphoma
Studies B-Cell Lymphoma
19 reported clinical trials
37 drugs studied
Mamta ParikhUniversity of California Davis Comprehensive Cancer Center8 years of reported clinical research
Expert in Cancer
Studies Bladder Cancer
21 reported clinical trials
36 drugs studied
Jonathan W. RiessUniversity of California Davis Comprehensive Cancer Center4 years of reported clinical research
Expert in Cancer
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
30 drugs studied
Clinical Trials running at Fremont - Rideout Cancer Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Bladder Cancer
Cancer
Urothelial Carcinoma
Squamous Cell Carcinoma
Colorectal Cancer
Multiple Myeloma
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This study is evaluating whether a support program may help breast cancer patients take their medication correctly.
Recruiting2 awards Phase 34 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Fremont - Rideout Cancer Center?
Fremont - Rideout Cancer Center is a medical facility located in Marysville, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Fremont - Rideout Cancer Center is involved with conducting 118 clinical trials across 260 conditions. There are 16 research doctors associated with this hospital, such as Edward J. Kim, Joseph M. Tuscano, Mamta Parikh, and Jonathan W. Riess.